What lorazepam dose should be given to a patient with a Withdrawal Assessment Scale (WAS) score of 22 for severe alcohol withdrawal?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Lorazepam Dosing for Severe Alcohol Withdrawal (WAS Score 22)

For a patient with a WAS score of 22 indicating severe alcohol withdrawal, initiate lorazepam at 1-4 mg IV/IM every 4-8 hours, starting at the higher end of this range (2-4 mg) given the severity, with a typical total daily dose of 6-12 mg/day that should be tapered as symptoms resolve. 1

Understanding the Clinical Context

A WAS (Withdrawal Assessment Scale) score of 22 represents severe alcohol withdrawal syndrome (AWS) requiring aggressive pharmacological intervention. While the provided evidence primarily references CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol-Revised) rather than WAS specifically, the principles of benzodiazepine dosing for severe withdrawal remain consistent across validated assessment scales.

Evidence-Based Dosing Strategy

Initial Dosing

The Korean Association for the Study of the Liver (KASL) 2013 guidelines specifically recommend 1:

  • Lorazepam: 1-4 mg PO/IV/IM every 4-8 hours
  • Starting daily dose: 6-12 mg/day for severe AWS
  • Taper following resolution of withdrawal symptoms

Route Selection

Lorazepam is specifically recommended for patients with:

  • Severe AWS (your patient qualifies)
  • Advanced age
  • Liver failure or hepatic dysfunction
  • Respiratory failure
  • Other serious medical comorbidities
  • Obesity

This is because lorazepam is an intermediate-acting benzodiazepine with no active metabolites, making it safer in hepatically compromised patients compared to long-acting agents like diazepam or chlordiazepoxide 1.

Practical Dosing Algorithm

For WAS Score 22 (Severe Withdrawal):

  1. Initial dose: 2-4 mg IV/IM (start at higher end given severity)

  2. Reassess in 1 hour using your withdrawal scale

  3. Repeat dosing:

    • If symptoms persist or worsen: Give another 2-4 mg
    • Continue every 4-8 hours as needed based on symptom severity
    • Target total daily dose: 6-12 mg/day initially

  4. Symptom-triggered approach preferred over fixed-dose scheduling to prevent drug accumulation 2

FDA-Approved Dosing Parameters

The FDA label for lorazepam injection provides additional context 3:

  • Standard anxiolysis/sedation: 2 mg IV or 0.044 mg/kg (whichever is smaller)
  • Maximum rate: 2 mg/minute IV
  • For elderly patients: Start lower (e.g., 1-2 mg) and titrate gradually

Critical Management Considerations

Symptom-Triggered vs. Fixed-Dose

The EASL 2018 guidelines emphasize that symptom-triggered regimens are superior to fixed-dose schedules, as they prevent benzodiazepine accumulation while adequately treating withdrawal 2. This means:

  • Dose based on current withdrawal severity
  • Reassess frequently (every 1-4 hours initially)
  • Adjust dosing as symptoms evolve

Essential Adjunctive Therapy

Thiamine must be administered to all patients with AWS 1:

  • 100-300 mg/day for prevention of Wernicke encephalopathy
  • Give before administering IV glucose (glucose can precipitate acute thiamine deficiency)
  • Continue for 2-3 months following resolution of withdrawal

Monitoring Requirements

For severe AWS (score 22), your patient requires:

  • Inpatient admission (recommended for serious complications) 1
  • Frequent vital sign monitoring
  • Evaluation for complications: dehydration, electrolyte imbalances, infection, GI bleeding
  • Psychiatric consultation for evaluation and long-term abstinence planning 1

Common Pitfalls to Avoid

  1. Underdosing in severe withdrawal: A score of 22 indicates significant symptoms requiring adequate benzodiazepine dosing. Don't be timid—inadequate treatment increases risk of seizures and delirium tremens.

  2. Ignoring hepatic dysfunction: If your patient has liver disease, lorazepam is the correct choice (no dose adjustment needed for acute dosing) 3, but avoid long-acting agents.

  3. Forgetting thiamine: This is non-negotiable and must precede glucose administration 1.

  4. Fixed-dose scheduling: Use symptom-triggered dosing to minimize total benzodiazepine exposure while maintaining symptom control 2.

  5. Prolonged benzodiazepine use: Taper and discontinue within 10-14 days to avoid dependence 2.

Comparative Evidence

Research demonstrates that lorazepam is non-inferior to chlordiazepoxide in reducing alcohol withdrawal symptoms 4, and when compared to diazepam, both are equally efficacious for severe AWS 5. The choice between agents should be guided by:

  • Patient factors (age, liver function, comorbidities)
  • Cost (lorazepam is significantly less expensive than diazepam) 5
  • Availability

Meta-analysis confirms that benzodiazepines reduce withdrawal severity, decrease delirium by 4.9 cases per 100 patients, and reduce seizures by 7.7 per 100 patients 6.

Tapering Strategy

Once symptoms improve (typically after 24-72 hours):

  • Reduce dose by 10-20% per day 7
  • Can also increase dosing intervals: every 6h → every 8h → every 12h → every 24h → discontinue
  • Monitor for symptom recurrence during taper

References

7
Guideline

neonatal drug withdrawal.

Pediatrics, 2012

Related Questions

What medication is first-line for managing alcohol withdrawal in an adult with uncomplicated withdrawal?
What is the Clinical Institute Withdrawal Assessment for Alcohol (CIWA‑Ar) scoring system, its interpretation, and recommended treatment thresholds?
How should agitation and hostility be managed in a 65-year-old male nursing home resident undergoing phenobarbital treatment for alcohol withdrawal?
What is the recommended assessment and pharmacologic management for alcohol withdrawal?
In a male patient who is not a daily alcohol consumer but drank continuously for three days and then stopped, is he at risk for alcohol withdrawal?
What diagnostic workup is recommended for a 35-year-old man with a three-month history of malaise?
Which of the following statements about Churg‑Strauss syndrome is correct? a) The central nervous system is typically affected. b) Positive antineutrophil cytoplasmic antibodies (ANCA) are characteristic in cases with renal involvement. c) Peripheral neuropathy presents with a stocking‑glove distribution. d) Peripheral blood eosinophilia is 5%.
What is the appropriate management for a patient presenting with urticaria and a fever of 38 °C?
In a patient with bandemia, no recent hospitalization, and currently on levofloxacin, should a broad-spectrum antibiotic be added?
Can imipenem be used to treat respiratory infections?
In a 43-year-old man with a history of intravenous drug use who presents with several days of lower leg cellulitis, is ceftriaxone adequate or should he be treated with vancomycin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.